Leflunomide+Vemurafenib in V600 Mutant Met. Melanoma

NCT01611675 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

3

Enrollment

OTHER

Sponsor class

Stopped Adverse Events

Conditions

Melanoma

Interventions

DRUG: Vemurafenib
DRUG: Leflunomide

Sponsor

Massachusetts General Hospital